An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ASP 5878 (Primary)
- Indications Bladder cancer; Breast cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 21 Mar 2020 Results of an analysis on extended systems model to describing changes in serum P, C, parathyroid hormone and Fibroblast growth factor receptor inhibition were presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 30 Apr 2019 Results published in the Investigational New Drugs Journal.
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.